Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* Necitumumab (Portrazza) is a new epidermal growth factor receptor antagonist approved to treat advanced squamous non-small cell lung cancer in patients who haven't received medication for advanced lung cancer.

 

* Risks include cardiac arrest and hypomagnesemia. The latter is extremely common. Electrolyte levels should be monitored closely.